GlassScriptPhysician profile
Cathy J Perry
NPI 1831421312
$3,526.80
in general payments reported to CMS, 2019-2025
46 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.96 · 2022: $72.66 · 2023: $760 · 2024: $1,246 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,330 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,330.18 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.56 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $264.63 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $256.25 | 2023-2025 | Calquence, Lynparza, Tagrisso |
| Pfizer INC. | $228.64 | 2024-2025 | |
| Daiichi Sankyo INC. | $218.04 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $158.90 | 2023-2025 | |
| Celgene Corporation | $153.89 | 2023-2025 | Pomalyst, Reblozyl |
| Gilead Sciences, INC. | $142.75 | 2022-2024 | Trodelvy |
| Beigene USA, INC. | $131.67 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $109.77 | 2023-2025 | Darzalex, Talvey, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $101.63 | 2021-2025 | Opdualag, Opdivo, Krazati |
| Pharmacyclics LLC, An Abbvie Company | $97.85 | 2022-2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $87.89 | 2024-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $79.43 | 2023-2024 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $76.18 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $65.66 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $63.50 | 2024 | Onivyde |
| Dendreon Pharmaceuticals LLC | $62.78 | 2024 | Provenge |
| Eisai INC. | $60.55 | 2023-2024 | |
| Glaxosmithkline, LLC. | $59.01 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Astellas Pharma US INC | $58.87 | 2024-2025 | Padcev |
| Sumitomo Pharma America, INC. | $57.16 | 2024-2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $53.92 | 2023-2025 | Ninlaro, Iclusig |
| Exelixis INC. | $50.73 | 2025 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $50.63 | 2024-2025 | |
| Seagen INC. | $49.51 | 2021-2023 | Tukysa, Padcev |
| Pharmaessentia USA Corporation | $40.03 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $38.44 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $37.93 | 2023-2024 | Zoladex |
| Genentech USA, INC. | $35.96 | 2023-2025 | Venclexta, Tecentriq |
| Springworks Therapeutics, INC. | $30.79 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $30.63 | 2025 | Romvimza, Qinlock |
| Rayner Intraocular Lenses Limited | $29.46 | 2024 | Rayone Spheric, Omidria, Rayone Emv |
| Adc Therapeutics America, INC. | $26.51 | 2024 | |
| Emd Serono, INC. | $24.97 | 2024 | |
| Genmab U.S., INC. | $24.94 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $24.66 | 2025 | Xpovio |
| Iovance Biotherapeutics, INC. | $24.54 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $23.04 | 2024 | Orserdu |
| Genzyme Corporation | $21.05 | 2024 | |
| Fennec Pharmaceuticals, INC. | $18.81 | 2025 | Fyarro |
| Incyte Corporation | $18.71 | 2023 | Jakafi, Monjuvi, Zynyz |
| Cycle Pharmaceuticals INC | $18.63 | 2025 | Phyrago |
| Servier Pharmaceuticals LLC | $17.80 | 2024 | |
| Lilly USA, LLC | $17.53 | 2023 | Jaypirca, Verzenio |
| Pharmacosmos Therapeutics INC. | $13.97 | 2025 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.